Travere Therapeutics, Inc. 8-K

What Happened
Travere Therapeutics announced it completed a registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032 on May 11, 2026. The offering was led by J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC. The Notes were issued under an indenture with U.S. Bank Trust Company, N.A. as trustee. Interest on the Notes is 0.50% per year, payable semi‑annually beginning November 15, 2026, and the Notes mature on May 15, 2032.

Key Details

• Offering size and terms: $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due May 15, 2032.
• Conversion mechanics: initial conversion rate of 15.4078 shares per $1,000 principal (implying an initial conversion price of ~ $64.90/share). The filing also notes a stated initial maximum conversion rate of 22.3413 shares per $1,000 (up to 11,729,182 shares), subject to anti‑dilution adjustments. Conversions may be settled in cash, shares, or a combination, at the company’s election.
• Conversion and redemption triggers: holders can convert only after specified stock‑price and other events (including periodic tests after the quarter ending Sept 30, 2026), and the company may redeem the Notes on or after May 21, 2029 if certain stock‑price conditions are met; limited partial‑redemption rules apply (company may not redeem less than all unless ≥ $75M remains outstanding).
• Other protections: Notes are senior unsecured obligations; the indenture contains customary default events, make‑whole/fundamental change provisions, and restrictions on mergers or asset sales unless an appropriate successor assumes the obligations.

Why It Matters
This transaction raises $525 million of relatively low‑cost financing (0.50% coupon) that provides Travere with additional capital while deferring cash interest costs. For shareholders, the key considerations are potential dilution and conversion risk: depending on future stock‑price movements and indenture adjustments, up to the stated number of shares could be issued upon conversion (or conversions may be settled in cash). The Notes are senior unsecured debt with customary default triggers and limited early redemption mechanics, so investors should watch for future conversion, redemption notices, and any disclosures about use of proceeds or changes to share count.